drugset / Trial / NCT03934450

Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers Receiving a Seven Day Dose Regimen

NCT03934450

Phase 1 Completed 36 enrolled University of Mississippi, Oxford
Non-randomizedCrossoverSingle-blindBasic science

Summary

To investigate the comparative tolerability, metabolism and pharmacokinetics of individual enantiomers of PQ in healthy human volunteers, receiving study drug over the course of 7 days.

Timeline

Start
2018-08-17
Primary completion
2019-05-01
Completion
2019-05-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Primaquine Small molecule 30 mg
Comparator Primaquine Small molecule 45 mg
Subject RPQ Unknown 15 mg
Subject RPQ Unknown 22.5 mg
Comparator SPQ Unknown 15 mg
Comparator SPQ Unknown 22.5 mg

Indications